XHKG
9969
Market cap2.06bUSD
May 30, Last price
11.26HKD
1D
3.87%
1Q
22.26%
IPO
15.84%
Name
InnoCare Pharma Ltd
Chart & Performance
P/E
—
P/S
14.70
EPS
—
Div Yield, %
—
Shrs. gr., 5y
6.20%
Rev. gr., 5y
281.63%
Revenues
1.01b
+36.68%
Net income
-441m
L-30.20%
CFO
0k
P
Earnings
Jun 27, 2025
Profile
InnoCare Pharma Limited, a biopharmaceutical company, engages in discovering, developing, and commercializing drugs for the treatment of cancer and autoimmune diseases. It develops Orelabrutinib, an BTK inhibitor to treat patients with relapsed and/or refractory (r/r) chronic lymphocytic leukemia, r/r mantle cell lymphoma, r/r Waldenstrom's macroglobulinemia, r/r marginal zone lymphoma, r/r diffuse large B-cell lymphoma (DLBCL)- MCD, r/r central nervous system lymphoma, combo w/MIL-62, systemic lupus erythematosus, immune thrombocytopenia purpura, multiple sclerosis, and neuromyelitis optica spectrum disorder. The company is also developing ICP-192, a pan-FGFR inhibitor that is in a Phase I/II clinical trial for the treatment of solid tumor patients, including cholangiocarcinoma, and head and neck cancer; ICP-723, a pan-TRK inhibitor, which is in Phase I clinical trial to treat neurotrophic tyrosine receptor kinase fusion positive cancers; ICP-332, a novel tyrosine kinase 2 inhibitor that is in a Phase I clinical trial for the treatment of autoimmune diseases; and ICP-B02, a bispecific antibody for the treatment of lymphoma. In addition, it develops ICP-189, ICP-915, and ICP-B03 for the treatment of solid tumors; ICP-033 to treat liver cancer, renal cell carcinoma, colorectal cancer, and other solid tumors; ICP-488 for the treatment of autoimmune diseases; ICP-B05, an anti-CC chemokine receptor 8 monoclonal antibody for the treatment of various cancers; ICP-248 to treat hematology; and ICP-490 for the treatment of hematology and autoimmune diseases. Further, it offers ICP-B04 (Tafasitamab) to treat DLBCL/hematology. InnoCare Pharma Limited was incorporated in 2015 and is headquartered in Beijing, China.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | |
| Income | ||||||||
Revenues | 1,009,448 36.68% | 738,537 18.09% | 625,404 -40.04% | |||||
Cost of revenue | 1,541,053 | 1,137,814 | 1,272,146 | |||||
Unusual Expense (Income) | ||||||||
NOPBT | (531,605) | (399,277) | (646,742) | |||||
NOPBT Margin | ||||||||
Operating Taxes | 263 | 1,426 | (22,077) | |||||
Tax Rate | ||||||||
NOPAT | (531,868) | (400,703) | (624,665) | |||||
Net income | (440,633) -30.20% | (631,263) -27.58% | (871,650) 1,207.23% | |||||
Dividends | (1,153) | (3,263) | ||||||
Dividend yield | 0.01% | 0.02% | ||||||
Proceeds from repurchase of equity | 3,647 | 2,923,230 | ||||||
BB yield | -0.03% | -14.48% | ||||||
| Debt | ||||||||
Debt current | 225,405 | 1,274,364 | 1,217,280 | |||||
Long-term debt | 1,408,322 | 136,827 | 90,990 | |||||
Deferred revenue | 278,203 | |||||||
Other long-term liabilities | 251,281 | 574,483 | 287,761 | |||||
Net debt | (4,589,299) | (6,819,065) | (7,401,369) | |||||
| Cash flow | ||||||||
Cash from operating activities | (671,340) | (565,554) | ||||||
CAPEX | (254,544) | (370,327) | ||||||
Cash from investing activities | 666,914 | (1,726,354) | ||||||
Cash from financing activities | 1,308 | 3,094,506 | ||||||
FCF | (1,270,878) | (537,529) | (1,074,512) | |||||
| Balance | ||||||||
Cash | 6,222,626 | 8,224,596 | 9,011,217 | |||||
Long term investments | 400 | 5,660 | (301,578) | |||||
Excess cash | 6,172,554 | 8,193,329 | 8,678,369 | |||||
Stockholders' equity | 6,749,032 | (5,021,311) | (4,375,679) | |||||
Invested Capital | 2,399,341 | 14,120,810 | 13,806,109 | |||||
ROIC | ||||||||
ROCE | ||||||||
| EV | ||||||||
Common stock shares outstanding | 1,690,850 | 1,706,116 | 1,479,565 | |||||
Price | 6.12 -11.18% | 6.89 -49.49% | 13.64 -10.85% | |||||
Market cap | 10,348,002 -11.97% | 11,755,139 -41.75% | 20,181,267 -3.46% | |||||
EV | 5,779,337 | 4,968,930 | 12,863,435 | |||||
EBITDA | (531,605) | (306,656) | (578,339) | |||||
EV/EBITDA | ||||||||
Interest | 35,031 | 17,045 | ||||||
Interest/NOPBT | ||||||||